CorMatrix Cardiovascular said today that it launched a trial of its Cor Tricuspid ECM cardiac valve intended for treating adults with endocarditis and pediatric patients with congenital heart valve disease, adding that the first patient in the trial has already been treated. The first procedure in the trial took place at the Francicscan Health Heart Center [...]The post CorMatrix launches FDA IDE Cor Tricuspid ECM cardiac valve trial appeared first on MassDevice.
